Advanced search
Publication Cover
Gut Microbes Volume 16, 2024 - Issue 1
Submit an article Journal homepage
1,251
Views
0
CrossRef citations to date
0
Altmetric
Review

The gut microbiome in disorders of gut–brain interaction

Narjis KraimiFarncombe Family Digestive Health Research Institute, McMaster University, Hamilton, CanadaView further author information
,
Taylor RossFarncombe Family Digestive Health Research Institute, McMaster University, Hamilton, CanadaView further author information
,
Julien PujoFarncombe Family Digestive Health Research Institute, McMaster University, Hamilton, CanadaView further author information
&
Giada De PalmaFarncombe Family Digestive Health Research Institute, McMaster University, Hamilton, CanadaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2063-7741View further author information
ORCID Icon
Article: 2360233 | Received 30 Jan 2024, Accepted 21 May 2024, Published online: 01 Jul 2024

References

  • Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, Whitehead WE, Dumitrascu DL, Fang X, Fukudo S. et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation global study. Gastroenterology. 2021;160(1):99–114.e3. doi:10.1053/j.gastro.2020.04.014.
  • Drossman DA, Hasler WL. Rome IV—functional GI disorders: disorders of gut-brain interaction. Gastroenterology. 2016;150(6):1257–28. doi:10.1053/j.gastro.2016.03.035.
  • Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IV. Gastroenterology. 2016;150(6):1262–1279.e2. doi:10.1053/j.gastro.2016.02.032.
  • Goodoory VC, Guthrie EA, Ng CE, Black CJ, Ford AC. Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome. Aliment Pharmacol Ther. 2023;57(3):323–334. doi:10.1111/apt.17356.
  • Black CJ, Ng CE, Goodoory VC, Ford AC. Novel symptom subgroups in individuals with irritable bowel syndrome predict disease impact and burden. Clin Gastroenterol Hepatol. 2023;22(2):386–396. doi:10.1016/j.cgh.2023.02.016.
  • Knowles SR, Skvarc D, Ford AC, Palsson OS, Bangdiwala SI, Sperber AD, Mikocka-Walus A. Negative impact of disorders of gut-brain interaction on health-related quality of life: results from the Rome foundation global epidemiology survey. Gastroenterology. 2023;164(4):655–668. doi:10.1053/j.gastro.2022.12.009.
  • Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;130(5):1377–1390. doi:10.1053/j.gastro.2006.03.008.
  • Yan L, Zhang X, Li Y, Liu C, Yang H, Yang C. The role of psychological factors in functional gastrointestinal disorders: a systematic review and meta-analysis. Int J Colorectal Dis. 2023;38(1):38. doi:10.1007/s00384-023-04333-9.
  • Mayer EA, Ryu HJ, Bhatt RR. The neurobiology of irritable bowel syndrome. Mol Psychiatry. 2023;28(4):1451–1465. doi:10.1038/s41380-023-01972-w.
  • Collins SM, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol. 2012;10(11):735–742. doi:10.1038/nrmicro2876.
  • Mayer EA, Tillisch K, Gupta A. Gut/brain axis and the microbiota. J Clin Invest. 2015;125(3):926–938. doi:10.1172/JCI76304.
  • Rajilić-Stojanović M, Biagi E, Heilig HGHJ, Kajander K, Kekkonen RA, Tims S, De Vos WM. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. 2011;141(5):1792–1801. doi:10.1053/j.gastro.2011.07.043.
  • Simreń M, Barbara G, Flint HJ, Spiegel BMR, Spiller RC, Vanner S, Verdu EF, Whorwell PJ, Zoetendal EG. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013;62(1):159–176. doi:10.1136/gutjnl-2012-302167.
  • Mars RAT, Yang Y, Ward T, Houtti M, Priya S, Lekatz HR, Tang X, Sun Z, Kalari KR, Korem T. et al. Longitudinal multi-omics reveals subset-specific mechanisms underlying irritable bowel syndrome. Cell. 2020;182(6):1460–1473. doi:10.1016/j.cell.2020.08.007.
  • Wernroth ML, Peura S, Hedman AM, Hetty S, Vicenzi S, Kennedy B, Fall K, Svennblad B, Andolf E, Pershagen G. et al. Development of gut microbiota during the first 2 years of life. Sci Rep. 2022;12(1):1–13. doi:10.1038/s41598-022-13009-3.
  • Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, Magris M, Hidalgo G, Baldassano RN, Anokhin AP. et al. Human gut microbiome viewed across age and geography. Nature. 2012;486(7402):222–227. doi:10.1038/nature11053.
  • Walker AW, Hoyles L. Human microbiome myths and misconceptions. Nat Microbiol. 2023;8(8):1392–1396. doi:10.1038/s41564-023-01426-7.
  • Goodrich JK, Waters JL, Poole AC, Sutter JL, Koren O, Blekhman R, Beaumont M, Van Treuren W, Knight R, Bell JT. et al. Human genetics shape the gut microbiome. Cell. 2014;159(4):789–799. doi:10.1016/j.cell.2014.09.053.
  • Farré-Maduell E, Casals-Pascual C. The origins of gut microbiome research in Europe: from Escherich to Nissle. Hum Microb J. 2019;14:14. doi:10.1016/j.humic.2019.100065.
  • Escherich T. Die darmbakterien des säuglings und ihre beziehungen zur physiologie der Verdauung. Stuttgart: F. Enke; 1886.
  • Escherich T. Die Darmbakterien des Neugeborenen und Sauglings. Fortschr Med. 1885;3(16 und 17):515–554.
  • Metchnikoff E. La Vieillesse. Rev Sci. 1904;2:65–70, 100–5.
  • Tissier H, Gasching P. Recherches sur la fermentation du lait. Ann l’Institut Pasteur. 1903;8:540–563.
  • Tissier H. Étude d’une varieté d’infection intestinale chez le nourrisson. Ann l’Institut Pasteur. 1905;1:273–316.
  • Nissle A, Nissle A. Über die Grundlagen einer neuen ursächlichen Bekämpfung der pathologischen Darmflora. Deutsche Medizinische Wochenschrift. 1916;42:1181–1184.
  • Anitha M, Vijay-Kumar M, Sitaraman SV, Gewirtz AT, Srinivasan S. Gut microbial products regulate murine gastrointestinal motility via toll-like receptor 4 signaling. Gastroenterology. 2012;143(4):1006–1016. doi:10.1053/j.gastro.2012.06.034.
  • De Vadder F, Grasset E, Mannerås Holm L, Karsenty G, Macpherson AJ, Olofsson LE, Bäckhed F. Gut microbiota regulates maturation of the adult enteric nervous system via enteric serotonin networks. Proc Natl Acad Sci U S A. 2018;115(25):6458–6463. doi:10.1073/pnas.1720017115.
  • Yarandi SS, Kulkarni S, Saha M, Sylvia KE, Sears CL, Pasricha PJ. Intestinal bacteria maintain adult enteric nervous system and nitrergic neurons via toll-like receptor 2-induced neurogenesis in mice. Gastroenterology. 2020;159(1):200–213. doi:10.1053/j.gastro.2020.03.050.
  • Obata Y, Castaño Á, Boeing S, Bon-Frauches AC, Fung C, Fallesen T, de Agüero MG, Yilmaz B, Lopes R, Huseynova A. et al. Neuronal programming by microbiota regulates intestinal physiology. Nature. 2020;578(7794):284–289. doi:10.1038/s41586-020-1975-8.
  • Hapfelmeier S, A E LM, Slack E, Kirundi JK, Stoel M, Heikenwalder M, Cahenzli J, Velykoredko Y, Balmer ML, Endt K. et al. Reversible microbial colonization of germ-free mice reveals the dynamics of IgA immune responses. Science. 2010;328(5986):1705–1709. doi:10.1126/science.1188454.
  • Olszak T, An D, Zeissig S, Vera MP, Richter J, Franke A, Glickman JN, Siebert R, Baron RM, Kasper DL. et al. Microbial exposure during early life has persistent effects on natural killer T cell function. Science (1979). 2012;336(6080):489–493. doi:10.1126/science.1219328.
  • Slack E, Hapfelmeier S, Stecher B, Velykoredko Y, Stoel M, Lawson MAE, Geuking MB, Beutler B, Tedder TF, Hardt WD. et al. Innate and adaptive immunity cooperate flexibly to maintain host-microbiota mutualism. Science (1979). 2009;325(5940):617–620. doi:10.1126/science.1172747.
  • Geuking MB, Cahenzli J, Lawson MAE, Dck N, Slack E, Hapfelmeier S, Kd M, Macpherson AJ. Intestinal bacterial colonization induces mutualistic regulatory T cell responses. Immunity. 2011;34(5):794–806. doi:10.1016/j.immuni.2011.03.021.
  • Collins J, Borojevic R, Verdu EF, Huizinga JD, Ratcliffe EM. Intestinal microbiota influence the early postnatal development of the enteric nervous system. Neurogastroent Motil. 2014;26(1):98–107. doi:10.1111/nmo.12236.
  • Li C, Stražar M, Mohamed AMT, Pacheco JA, Walker RL, Lebar T, et al. Gut microbiome and metabolome profiling in Framingham heart study reveals cholesterol-metabolizing bacteria. Cell 2024; 187:1834-52.e19. doi:10.1016/j.cell.2024.03.014.
  • Pellanda P, Ghosh TS, O’Toole PW. Understanding the impact of age-related changes in the gut microbiome on chronic diseases and the prospect of elderly-specific dietary interventions. Curr Opin Biotechnol. 2021;70:48–55. doi:10.1016/j.copbio.2020.11.001.
  • Cӑtoi AF, Corina A, Katsiki N, Vodnar DC, Andreicuț AD, Stoian AP, Rizzo M, Pérez-Martínez P. Gut microbiota and aging – a focus on centenarians. Biochim Biophys Acta Mol Basis Dis. 2020;1866(7):165765. doi:10.1016/j.bbadis.2020.165765.
  • Bai X, De Palma G, Boschetti E, Nishihara Y, Lu J. Vasoactive intestinal polypeptide plays a key role in the microbial-neuroimmune control of intestinal motility. Cell Mol Gastroenterol Hepatol. 2023;17(3):383–398. doi:10.1016/j.jcmgh.2023.11.012.
  • Luczynski P, Tramullas M, Viola M, Shanahan F, Clarke G, Mahony SO, Dinan TG, Cryan JF. Microbiota regulates visceral pain in the mouse. Elife. 2017;6:1–21. doi:10.7554/eLife.25887.
  • Esquerre N, Basso L, Defaye M, Vicentini FA, Cluny N, Bihan D, Hirota SA, Schick A, Jijon HB, Lewis IA. et al. Colitis-induced microbial perturbation promotes postinflammatory visceral hypersensitivity. Cmgh. 2020;10(2):225–244. doi:10.1016/j.jcmgh.2020.04.003.
  • Gao J, Xiong T, Grabauskas G, Owyang C. Mucosal serotonin reuptake transporter expression in irritable bowel syndrome is modulated by gut microbiota via mast cell–prostaglandin E2. Gastroenterology. 2022;162(7):1962–1974. doi:10.1053/j.gastro.2022.02.016.
  • Lucarini E, Di Pilato V, Parisio C, Micheli L, Toti A, Pacini A, Bartolucci G, Baldi S, Niccolai E, Amedei A. et al. Visceral sensitivity modulation by faecal microbiota transplantation: the active role of gut bacteria in pain persistence. Pain. 2022;163(5):861–877. doi:10.1097/j.pain.0000000000002438.
  • Amaral FA, Sachs D, Costa VV, Fagundes CT, Cisalpino D, Cunha TM, Ferreira SH, Cunha FQ, Silva TA, Nicoli JR. et al. Commensal microbiota is fundamental for the development of inflammatory pain. Proc Natl Acad Sci U S A. 2008;105(6):2193–2197. doi:10.1073/pnas.0711891105.
  • Shen S, Lim G, You Z, DIng W, Huang P, Ran C, Doheny J, Caravan P, Tate S, Hu K. et al. Gut microbiota is critical for the induction of chemotherapy-induced pain. Nat Neurosci. 2017;20(9):1213–1216. doi:10.1038/nn.4606.
  • Chiu IM, Heesters BA, Ghasemlou N, Von Hehn CA, Zhao F, Tran J, Wainger B, Strominger A, Muralidharan S, Horswill AR. et al. Bacteria activate sensory neurons that modulate pain and inflammation. Nature. 2013;501(7465):52–57. doi:10.1038/nature12479.
  • Pujo J, De Palma G, Lu J, Galipeau HJ, Surette MG, Collins SM, Bercik P. Gut microbiota modulates visceral sensitivity through calcitonin gene-related peptide (CGRP) production. Gut Microbes. 2023;15(1):2188874. doi:10.1080/19490976.2023.2188874.
  • Lin X, Hu T, Chen J, Liang H, Zhou J, Wu Z, Ye C, Jin X, Xu X, Zhang W. et al. The genomic landscape of reference genomes of cultivated human gut bacteria. Nat Commun. 2023;14(1):1–11. doi:10.1038/s41467-023-37396-x.
  • Siegwald L, Audebert C, Even G, Viscogliosi E, Caboche S, Chabé M. Targeted metagenomic sequencing data of human gut microbiota associated with Blastocystis colonization. Sci Data. 2017;4(1):1–7. doi:10.1038/sdata.2017.81.
  • Rehan M, Al-Bahadly I, Thomas DG, Young W, Cheng LK, Avci E. Smart capsules for sensing and sampling the gut: status, challenges and prospects. Gut. 2023;73(1):186–202. doi:10.1136/gutjnl-2023-329614.
  • Shalon D, Culver RN, Grembi JA, Folz J, Treit PV, Shi H, Rosenberger FA, Dethlefsen L, Meng X, Yaffe E. et al. Profiling the human intestinal environment under physiological conditions. Nature. 2023;617(7961):581–591. doi:10.1038/s41586-023-05989-7.
  • Asnicar F, Berry SE, Valdes AM, Nguyen LH, Piccinno G, Drew DA, Leeming E, Gibson R, Le Roy C, Khatib HA. et al. Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals. Nat Med. 2021;27(2):321–332. doi:10.1038/s41591-020-01183-8.
  • Kolodziejczyk AA, Zheng D, Elinav E. Diet–microbiota interactions and personalized nutrition. Nat Rev Microbiol. 2019;17(12):742–753. doi:10.1038/s41579-019-0256-8.
  • Zmora N, Suez J, Elinav E. You are what you eat: diet, health and the gut microbiota. Nat Rev Gastroenterol Hepatol. 2019;16(1):35–56. doi:10.1038/s41575-018-0061-2.
  • Caugant DA, Levin BR, Selander RK. Distribution of multilocus genotypes of Escherichia coli within and between host families. Epidemiol Infect. 1984;92(3):377–384. doi:10.1017/S0022172400064597.
  • Kates AE, Jarrett O, Skarlupka JH, Sethi A, Duster M, Watson L, Suen G, Poulsen K, Safdar N. Household pet ownership and the microbial diversity of the human gut microbiota. Front Cell Infect Microbiol. 2020;10:73. doi:10.3389/fcimb.2020.00073.
  • Tun HM, Konya T, Takaro TK, Brook JR, Chari R, Field CJ, Guttman DS, Becker AB, Mandhane PJ, Turvey SE. et al. Exposure to household furry pets influences the gut microbiota of infants at 3–4 months following various birth scenarios. Microbiome. 2017;5(1):1–14. doi:10.1186/s40168-017-0254-x.
  • Bajaj JS. Alcohol, liver disease and the gut microbiota. Nat Rev Gastroenterol Hepatol. 2019;16(4):235–246. doi:10.1038/s41575-018-0099-1.
  • Fluhr L, Mor U, Kolodziejczyk AA, Dori-Bachash M, Leshem A, Itav S, Cohen Y, Suez J, Zmora N, Moresi C. et al. Gut microbiota modulates weight gain in mice after discontinued smoke exposure. Nature. 2021;600(7890):713–719. doi:10.1038/s41586-021-04194-8.
  • Sarkar A, McInroy CJA, Harty S, Raulo A, Ibata NGO, Valles-Colomer M, Johnson K-A, Brito IL, Henrich J, Archie EA. et al. Microbial transmission in the social microbiome and host health and disease. Cell. 2024;187(1):17–43. doi:10.1016/j.cell.2023.12.014.
  • Wolf S. The psyche and the stomach. A historical vignette. Gastroenterology. 1981;80(3):605–614. doi:10.1016/0016-5085(81)90027-5.
  • Kleisiaris CF, Sfakianakis C, Papathanasiou IV. Health care practices in ancient Greece: the hippocratic ideal. J Med Ethics Hist Med. 2014;7:3–7.
  • Bercik P, Collins SM, Verdu EF. Microbes and the gut-brain axis. Neurogastroent Motil. 2012;24(5):405–413. doi:10.1111/j.1365-2982.2012.01906.x.
  • Buchanan KL, Rupprecht LE, Kaelberer MM, Sahasrabudhe A, Klein ME, Villalobos JA, Liu WW, Yang A, Gelman J, Park S. et al. The preference for sugar over sweetener depends on a gut sensor cell. Nat Neurosci. 2022;25(2):191–200. doi:10.1038/s41593-021-00982-7.
  • Han H, Yi B, Zhong R, Wang M, Zhang S, Ma J, Yin Y, Yin J, Chen L, Zhang H. From gut microbiota to host appetite: gut microbiota-derived metabolites as key regulators. Microbiome. 2021;9(1):1–16. doi:10.1186/s40168-021-01093-y.
  • Rogers GB, Keating DJ, Young RL, Wong M, Licinio J, Wesselingh S. From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways. Mol Psychiatry. 2016;21(6):738–748. doi:10.1038/mp.2016.50.
  • Steenbergen L, Sellaro R, Van HS, Bosch JA, Colzato LS. A randomized controlled trial to test the effect of multispecies probiotics on cognitive reactivity to sad mood q. Brain Behav Immun. 2015;48:258–264. doi:10.1016/j.bbi.2015.04.003.
  • Bagga D, Reichert JL, Koschutnig K, Aigner CS, Holzer P, Koskinen K, Moissl-Eichinger C, Schöpf V. Probiotics drive gut microbiome triggering emotional brain signatures. Gut Microbes. 2018;0:1–11. doi:10.1080/19490976.2018.1460015.
  • Johnson KVA, Foster KR. Why does the microbiome affect behaviour? Nat Rev Microbiol. 2018;16(10):647–655. doi:10.1038/s41579-018-0014-3.
  • Breit S, Kupferberg A, Rogler G, Hasler G. Vagus nerve as modulator of the brain-gut axis in psychiatric and inflammatory disorders. Front Psychiatry. 2018;9. doi:10.3389/fpsyt.2018.00044.
  • Price CJ, Hoyda TD, Ferguson AV. The area postrema: a brain monitor and integrator of systemic autonomic state. Neuroscientist. 2008;14(2):182–194. doi:10.1177/1073858407311100.
  • Liu WW, Bohórquez DV. The neural basis of sugar preference. Nat Rev Neurosci. 2022;23(10):584–595. doi:10.1038/s41583-022-00613-5.
  • Kaelberer MM, Buchanan KL, Klein ME, Barth BB, Montoya MM, Shen X, Bohórquez DV. A gut-brain neural circuit for nutrient sensory transduction. Science (1979). 2018;361(6408):361. doi:10.1126/science.aat5236.
  • Han W, Tellez LA, Perkins MH, Perez IO, Qu T, Ferreira J, Ferreira TL, Quinn D, Liu ZW, Gao XB. et al. A Neural Circuit for Gut-Induced Reward. Cell. 2018;175(3):665–678.
  • Arentsen T, Qian Y, Gkotzis S, Femenia T, Wang T, Udekwu K, Forssberg H, Heijtz RD. The bacterial peptidoglycan-sensing molecule Pglyrp2 modulates brain development and behavior. Mol Psychiatry. 2017;22(2):257–266. doi:10.1038/mp.2016.182.
  • Ochoa-Repáraz J, Mielcarz DW, Wang Y, Begum-Haque S, Dasgupta S, Kasper DL, Kasper LH. A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease. Mucosal Immunol. 2010;3(5):487–495. doi:10.1038/mi.2010.29.
  • Quan N, Stern EL, Whiteside MB, Herkenham M. Induction of pro-inflammatory cytokine mRnas in the brain after peripheral injection of subseptic doses of lipopolysaccharide in the rat. J Neuroimmunol. 1999;93(1–2):72–80. doi:10.1016/S0165-5728(98)00193-3.
  • Breder CD, Hazuka C, Ghayurt T, Klug C, Huginint M, Yasuda K, Tengii M, Saper CB. Regional induction of tumor necrosis factor alpha expression in the mouse brain after systemic lipopolysaccharide administration. Proc Natl Acad Sci USA. 1994;91(24):11393–11397. doi:10.1073/pnas.91.24.11393.
  • Elmquist JK, Scammell TE, Jacobson CD, Saper CB. Distribution of Fos-like immunoreactivity in the rat brain following intravenous lipopolysaccharide administration. J Comp Neurol. 1996;371(1):85–103. doi:10.1002/(SICI)1096-9861(19960715)371:1<85:AID-CNE5>3.0.CO;2-H.
  • Needham BD, Funabashi M, Adame MD, Wang Z, Boktor JC, Haney J, Wu WL, Rabut C, Ladinsky MS, Hwang SJ. et al. A gut-derived metabolite alters brain activity and anxiety behaviour in mice. Nature. 2022;602(7898):647–653. doi:10.1038/s41586-022-04396-8.
  • Stewart Campbell A, Needham BD, Meyer CR, Tan J, Conrad M, Preston GM, Bolognani F, Rao SG, Heussler H, Griffith R. et al. Safety and target engagement of an oral small-molecule sequestrant in adolescents with autism spectrum disorder: an open-label phase 1b/2a trial. Nat Med. 2022;28(3):528–534. doi:10.1038/s41591-022-01683-9.
  • Xia Y, Xiao Y, Wang ZH, Liu X, Alam AM, Haran JP, McCormick BA, Shu X, Wang X, Ye K. Bacteroides Fragilis in the gut microbiomes of Alzheimer’s disease activates microglia and triggers pathogenesis in neuronal C/EBPβ transgenic mice. Nat Commun. 2023;14(1):1–20. doi:10.1038/s41467-023-41283-w.
  • Hsiao EY, McBride SW, Hsien S, Sharon G, Hyde ER, McCue T, Codelli JA, Chow J, Reisman SE, Petrosino JF. et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell. 2013;155(7):1451–1463. doi:10.1016/j.cell.2013.11.024.
  • Wuchert F, Ott D, Murgott J, Rafalzik S, Hitzel N, Roth J, Gerstberger R. Rat area postrema microglial cells act as sensors for the toll-like receptor-4 agonist lipopolysaccharide. J Neuroimmunol. 2008;204(1–2):66–74. doi:10.1016/j.jneuroim.2008.07.017.
  • Laflamme N, Rivest S. Toll‐like receptor 4: the missing link of the cerebral innate immune response triggered by circulating gram‐negative bacterial cell wall components. Faseb J. 2001;15(1):155–163. doi:10.1096/fj.00-0339com.
  • Kraimi N, Vivek P, Zhang H, Lu J, De Palma G, Shimbori C, Verdu EF, McCoy KD, Hapfelmeier S, Macpherson AJ. et al. Microbial activation of intestinal dendritic cells is critical for the establishment of normal behavior. J Canadian Assoc Gastroenterol. 2023;6(Suppl Supplement_1):4–5. doi:10.1093/jcag/gwac036.008.
  • Dantzer R, Bluthé RM, Gheusi G, Cremona S, Layé S, Parnet P, Kelley KW. Molecular basis of sickness behavior a. Ann N Y Acad Sci. 1998;856(1):132–138. doi:10.1111/j.1749-6632.1998.tb08321.x.
  • Elmquist JK, Scammell TE, Saper CB. Mechanisms of CNS response to systemic immune challenge: the febrile response. Trends Neurosci. 1997;20(12):565–570. doi:10.1016/S0166-2236(97)01138-7.
  • Gaykema RPA, Goehler LE, Lyte M. Brain response to cecal infection with Campylobacter jejuni: analysis with Fos immunohistochemistry. Brain Behav Immun. 2004;18(3):238–245. doi:10.1016/j.bbi.2003.08.002.
  • Goehler LE, Gaykema RPA, Opitz N, Reddaway R, Badr N, Lyte M. Activation in vagal afferents and central autonomic pathways: early responses to intestinal infection with Campylobacter jejuni. Brain Behav Immun. 2005;19(4):334–344. doi:10.1016/j.bbi.2004.09.002.
  • Osterhout JA, Kapoor V, Eichhorn SW, Vaughn E, Moore JD, Liu D, Lee D, DeNardo LA, Luo L, Zhuang X. et al. A preoptic neuronal population controls fever and appetite during sickness. Nature. 2022;606(7916):937–944. doi:10.1038/s41586-022-04793-z.
  • Ilanges A, Shiao R, Shaked J, Luo JD, Yu X, Friedman JM. Brainstem ADCYAP1+ neurons control multiple aspects of sickness behaviour. Nature. 2022;609(7928):761–771. doi:10.1038/s41586-022-05161-7.
  • Pinho-Ribeiro FA, Deng L, Neel DV, Erdogan O, Basu H, Yang D, Choi S, Walker AJ, Carneiro-Nascimento S, He K. et al. Bacteria hijack a meningeal neuroimmune axis to facilitate brain invasion. Nature. 2023;615(7952):472–481. doi:10.1038/s41586-023-05753-x.
  • Servick K. Do gut bacteria make a second home in our brains. Science (1979). 2018;10:92. doi:10.1126/science.aaw0147.
  • Chaudhuri D, Chowdhury AR, Biswas B, Chakravortty D. Salmonella Typhimurium infection leads to colonization of the mouse brain and is not completely cured with antibiotics. Front Microbiol. 2018;9:1–12. doi:10.3389/fmicb.2018.01632.
  • Arabi TZ, Alabdulqader AA, Sabbah BN, Ouban A. Brain-inhabiting bacteria and neurodegenerative diseases: the “brain microbiome” theory. Front Aging Neurosci. 2023;15:1–9. doi:10.3389/fnagi.2023.1240945.
  • Peh A, Dinakis E, Nakai M, Muralitharan RR, Rupasinghe S, Wilson JL, Wong CHY, Jama H, Barker CMO, Modarresi M. et al. Gut bacteria translocation to the brain after ischaemic stroke occurs via the sympathetic nervous system. bioRxiv. 2023. doi:10.1101/2023.04.03.535309.
  • Thapa M, Kumari A, Chin C-Y, Choby JE, Jin F, Bogati B, Chopyk DM, Koduri N, Pahnke A, Elrod EJ. et al. Translocation of gut commensal bacteria to the brain. bioRxiv. 2023. doi:10.1101/2023.08.30.555630.
  • Hu X, Mckenzie C-A, Smith C, Haas JG, Lathe R. The remarkable complexity of the brain microbiome in health and disease. bioRxiv. 2023;2023–02. doi:10.1101/2023.02.06.527297.
  • Kennedy KM, de Goffau MC, Perez-Muñoz ME, Arrieta MC, Bäckhed F, Bork P, Braun T, Bushman FD, Dore J, de Vos WM. et al. Questioning the fetal microbiome illustrates pitfalls of low-biomass microbial studies. Nature. 2023;613(7945):639–649. doi:10.1038/s41586-022-05546-8.
  • Pérez-Berezo T, Pujo J, Martin P, Le Faouder P, Galano JM, Guy A, Knauf C, Tabet JC, Tronnet S, Barreau F. et al. Identification of an analgesic lipopeptide produced by the probiotic Escherichia coli strain Nissle 1917. Nat Commun. 2017;8(1):1–12. doi:10.1038/s41467-017-01403-9.
  • Lenard J. Mammalian hormones in microbial cells. Trends Biochem Sci. 1992;17(4):147–150. doi:10.1016/0968-0004(92)90323-2.
  • Minuk GY. Gamma-aminobutyric acid (GABA) production by eight common bacterial pathogens. Scand J Infect Dis. 1986;18(5):465–467. doi:10.3109/00365548609032366.
  • O’Donnell MP, Fox BW, Chao PH, Schroeder FC, Sengupta P. A neurotransmitter produced by gut bacteria modulates host sensory behaviour. Nature. 2020;583(7816):415–420. doi:10.1038/s41586-020-2395-5.
  • Asano Y, Hiramoto T, Nishino R, Aiba Y, Kimura T, Yoshihara K, Koga Y, Sudo N. Critical role of gut microbiota in the production of biologically active, free catecholamines in the gut lumen of mice. Am J Physiol Gastrointest Liver Physiol. 2012;303(11):G1288–G1295. doi:10.1152/ajpgi.00341.2012.
  • Li D, Liu R, Wang M, Peng R, Fu S, Fu A, Le J, Yao Q, Yuan T, Chi H. et al. 3β-Hydroxysteroid dehydrogenase expressed by gut microbes degrades testosterone and is linked to depression in males. Cell Host Microbe. 2022;30(3):329–339. doi:10.1016/j.chom.2022.01.001.
  • Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL. Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019;570(7762):462–467. doi:10.1038/s41586-019-1291-3.
  • Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL. Separating host and microbiome contributions to drug pharmacokinetics and toxicity. Science (1979). 2019;363(6427). doi:10.1126/science.aat9931.
  • Klünemann M, Andrejev S, Blasche S, Mateus A, Phapale P, Devendran S, Vappiani J, Simon B, Scott TA, Kafkia E. et al. Bioaccumulation of therapeutic drugs by human gut bacteria. Nature. 2021;597(7877):533–538. doi:10.1038/s41586-021-03891-8.
  • van Kessel SP, Frye AK, El-Gendy AO, Castejon M, Keshavarzian A, van Dijk G, El Aidy S, van Kessel SP. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease. Nat Commun. 2019;10(1):1–11. doi:10.1038/s41467-019-08294-y.
  • Rekdal VM, Bess EN, Bisanz JE, Turnbaugh PJ, Balskus EP. Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science (1979). 2019;364(6445). doi:10.1126/science.aau6323.
  • Mager LF, Burkhard R, Pett N, Cooke NCA, Brown K, Ramay H, Paik S, Stagg J, Groves RA, Gallo M. et al. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science (1979). 2020;369(6510):1481–1489. doi:10.1126/science.abc3421.
  • Drossman DA. Abuse, trauma, and GI illness: is there a link. Am J Gastroenterol. 2011;106(1):14–25. doi:10.1038/ajg.2010.453.
  • D’Amato M. Genes and functional GI disorders: from casual to causal relationship. Neurogastroent Motil. 2013;25(8):638–649. doi:10.1111/nmo.12173.
  • Geeraerts B, Van Oudenhove L, Fischler B, Vandenberghe J, Caenepeel P, Janssens J, Tack J. Influence of abuse history on gastric sensorimotor function in functional dyspepsia. Neurogastroent Motil. 2009;21(1):33–41. doi:10.1111/j.1365-2982.2008.01178.x.
  • Villarreal AA, Aberger FJ, Benrud R, Gundrum JD. Use of broad-spectrum antibiotics and the development of irritable bowel syndrome. Wis Med J. 2012;111:17–20.
  • Schmulson MJ, Drossman DA. What’s new in Rome IV? Neurogastroent Motil. 2017;29(2):151–163. doi:10.5056/jnm16214.
  • Siah KTH, Gong X, Yang XJ, Whitehead WE, Chen M, Hou X, Pratap N, Ghoshal UC, Syam AF, Abdullah M. et al. Rome foundation-asian working team report: Asian functional gastrointestinal disorder symptom clusters. Gut. 2018;67(6):1071–1077. doi:10.1136/gutjnl-2016-312852.
  • Holtmann GJ, Talley NJ. Inconsistent symptom clusters for functional gastrointestinal disorders in Asia: is Rome burning? Gut. 2018;67(11):1911–1915. doi:10.1136/gutjnl-2017-314775.
  • Hreinsson JP, Törnblom H, Tack J, Drossman DA, Whitehead WE, Bangdiwala SI, Sperber AD, Palsson OS, Simrén M. Factor analysis of the Rome IV criteria for major Disorders of Gut-Brain Interaction (DGBI) globally and across geographical, sex, and age groups. Gastroenterology. 2023;164(7):1211–1222. doi:10.1053/j.gastro.2023.02.033.
  • Almario CV, Sharabi E, Chey WD, Lauzon M, Higgins CS, Spiegel BMR. Prevalence and burden of illness of Rome IV irritable bowel syndrome in the United States: results from a nationwide cross-sectional study. Gastroenterology. 2023;165(6):1475–1487. doi:10.1053/j.gastro.2023.08.010.
  • Saffouri GB, Shields-Cutler RR, Chen J, Yang Y, Lekatz HR, Hale VL, Cho JM, Battaglioli EJ, Bhattarai Y, Thompson KJ. et al. Small intestinal microbial dysbiosis underlies symptoms associated with functional gastrointestinal disorders. Nat Commun. 2019;10(1):1–11. doi:10.1038/s41467-019-09964-7.
  • Brandt LJ, Chey WD, Foxx-Orenstein AE, Quigley EMM, Schiller LR, Schoenfeld PS, Spiegel BM, Talley NJ, Moayyedi P. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2008;104:7–10. doi:10.14309/00000434-200901001-00002.
  • Simrén M. Targeting the gut microenvironment in IBS to improve symptoms. Nat Rev Gastroenterol Hepatol. 2023;20(2):69–70. doi:10.1038/s41575-022-00718-3.
  • Camilleri M, Zhernakova A, Bozzarelli I, D’Amato M. Genetics of irritable bowel syndrome: shifting gear via biobank-scale studies. Nat Rev Gastroenterol Hepatol. 2022;19(11):689–702. doi:10.1038/s41575-022-00662-2.
  • Zamfir-Taranu A, Löscher BS, Husein DM, Hoter A, Garcia-Etxebarria K, Etxeberria U, Gayoso L, Mayr G, Nilholm C, Gustafsson RJ. et al. Sucrase-isomaltase genotype and response to a starch-reduced and sucrose-reduced diet in IBS-D patients. Gut. 2023;0:1–2. doi:10.1136/gutjnl-2023-329695.
  • Alemany S, Soler-Artigas M, Cabana-Domínguez J, Fakhreddine D, Llonga N, Vilar-Ribó L, Rodríguez-Urrutia A, Palacio J, González-Castro AM, Lobo B. et al. Genome-wide multi-trait analysis of irritable bowel syndrome and related mental conditions identifies 38 new independent variants. J Transl Med. 2023;21(1):21. doi:10.1186/s12967-023-04107-5.
  • Tanaka Y, Kanazawa M, Fukudo S, Drossman DA. Biopsychosocial model of irritable bowel syndrome. J Neurogastroenterol Motil. 2011;17(2):131–139. doi:10.5056/jnm.2011.17.2.131.
  • Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130(5):1480–1491. doi:10.1053/j.gastro.2005.11.061.
  • Byale A, Lennon RJ, Byale S, Breen-Lyles M, Edwinson AL, Gupta R, Lacy BE, Olson JE, Houghton LA, Grover M. High-dimensional clustering of 4000 irritable bowel syndrome patients reveals seven distinct disease subsets. Clinical Gastroenterology and Hepatology. 2024;22(1):173–184. doi:10.1016/j.cgh.2022.09.019.
  • Black CJ, Yiannakou Y, Guthrie EA, West R, Houghton LA, Ford AC. A novel method to classify and subgroup patients with IBS based on gastrointestinal symptoms and psychological profiles. Am J Gastroenterol. 2021;116(2):372–381. doi:10.14309/ajg.0000000000000975.
  • Ford AC, Mahadeva S, Carbone MF, Lacy BE, Talley NJ. Functional dyspepsia. Lancet. 2020;396(10263):1689–1702. doi:10.1016/S0140-6736(20)30469-4.
  • Mahadeva S, Goh KL. Epidemiology of functional dyspepsia: a global perspective. World J Gastroenterol. 2006;12(17):2661–2666. doi:10.3748/wjg.v12.i17.2661.
  • Barberio B, Yiannakou Y, Houghton LA, Black CJ, Savarino EV, Ford AC. Overlap of Rome IV irritable bowel syndrome and functional dyspepsia and effect on natural history: a longitudinal follow-up study. Clin Gastroenterol Hepatol. 2022;20(2):e89–101. doi:10.1016/j.cgh.2021.04.011.
  • Sperber AD, Freud T, Aziz I, Palsson OS, Drossman DA, Dumitrascu DL, Fang X, Fukudo S, Ghoshal UC, Kellow J. et al. Greater overlap of Rome IV disorders of gut-brain interactions leads to increased disease severity and poorer quality of life. Clin Gastroenterol Hepatol. 2022;20(5):e945–56. doi:10.1016/j.cgh.2021.05.042.
  • Fadgyas-Stanculete M, Buga A-M, Popa-Wagner A, Dumitrascu DL. The relationship between irritable bowel syndrome and psychiatric disorders: from molecular changes to clinical manifestations. J Mol Psychiatry. 2014;2(1):1–7. doi:10.1186/2049-9256-2-4.
  • De Palma G, Collins SM, Bercik P. The microbiota-gut-brain axis in functional gastrointestinal disorders. Gut Microbes. 2014;5(3):419–429. doi:10.4161/gmic.29417.
  • Jones MP, Dilley JB, Drossman D, Crowell MD. Brain–gut connections in functional GI disorders: anatomic and physiologic relationships. Neurogastroent Motil. 2006;18(2):91–103. doi:10.1111/j.1365-2982.2005.00730.x.
  • Trindade IA, Hreinsson JP, Melchior C, Algera JP, Colomier E, Törnblom H, Drossman D, Tack J, Palsson OS, Bangdiwala SI. et al. Global prevalence of psychological distress and comorbidity with disorders of gut-brain interactions. Am J Gastroenterol. 2023;119(1):165–175. doi:10.14309/ajg.0000000000002500.
  • Black CJ, Drossman DA, Talley NJ, Ruddy J, Ford AC. Functional gastrointestinal disorders: advances in understanding and management. Lancet. 2020;396(10263):1664–1674. doi:10.1016/S0140-6736(20)32115-2.
  • Drossman DA. Psychosocial factors and the disorders of GI function: what is the link? Am J Gastroenterol. 2004;99(2):358–360. doi:10.1111/j.1572-0241.2004.04076.x.
  • Van Oudenhove L, Levy RL, Crowell MD, Drossman DA, Halpert AD, Keefer L, Lackner JM, Murphy TB, Naliboff BD. Biopsychosocial aspects of functional gastrointestinal disorders: how central and environmental processes contribute to the development and expression of functional gastrointestinal disorders. Gastroenterology. 2016;150(6):1355–1367. doi:10.1053/j.gastro.2016.02.027.
  • Pinto-Sanchez MI, Ford AC, Avila CA, Verdu EF, Collins SM, Morgan D, Moayyedi P, Bercik P. Anxiety and depression increase in a stepwise manner in parallel with multiple FGIDs and symptom severity and frequency. Am J Gastroenterol. 2015;110(7):1038–1048. doi:10.1038/ajg.2015.128.
  • Van Oudenhove L, Törnblom H, Störsrud S, Tack J, Simrén M. Depression and somatization are associated with increased postprandial symptoms in patients with irritable bowel syndrome. Gastroenterology. 2016;150(4):866–874. doi:10.1053/j.gastro.2015.11.010.
  • Pohl D, Van Oudenhove L, Törnblom H, Le Nevé B, Tack J, Simrén M. Functional dyspepsia and severity of psychologic symptoms associate with postprandial symptoms in patients with irritable bowel syndrome. Clinical Gastroenterology and Hepatology. 2018;16(11):1745–1753. doi:10.1016/j.cgh.2018.04.034.
  • Midenfjord I, Polster A, Sjövall H, Törnblom H, Simrén M. Anxiety and depression in irritable bowel syndrome: exploring the interaction with other symptoms and pathophysiology using multivariate analyses. Neurogastroent Motil. 2019;31(8):1–14. doi:10.1111/nmo.13619.
  • Kim SY, Choung RS, Lee SK, Choe JW, Jung SW, Hyun JJ, Koo JS, Lee SW, Shin C. Self-reported sleep impairment in functional dyspepsia and irritable bowel syndrome. J Neurogastroenterol Motil. 2018;24(2):280–288. doi:10.5056/jnm17098.
  • Zamani M, Alizadeh-Tabari S, Zamani V. Systematic review with meta-analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2019;50(2):132–143. doi:10.1111/apt.15325.
  • Fond G, Loundou A, Hamdani N, Boukouaci W, Dargel A, Oliveira J, Roger M, Tamouza R, Leboyer M, Boyer L. Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2014;264(8):651–660. doi:10.1007/s00406-014-0502-z.
  • Lee C, Doo E, Choi JM, Ho JS, Ryu HS, Lee JY, Oh JH, Park JH, Kim YS. The increased level of depression and anxiety in irritable bowel syndrome patients compared with healthy controls: systematic review and meta-analysis. J Neurogastroenterol Motil. 2017;23(3):349–362. doi:10.5056/jnm16220.
  • Goodoory VC, Mikocka-Walus A, Yiannakou Y, Houghton LA, Black CJ, Ford AC. Impact of psychological comorbidity on the prognosis of irritable bowel syndrome. Am J Gastroenterol. 2021;116(7):1485–1494. doi:10.14309/ajg.0000000000001247.
  • Lee S, Wu J, Ma YL, Tsang A, Guo WJ, Sung J. Irritable bowel syndrome is strongly associated with generalized anxiety disorder: a community study. Aliment Pharmacol Ther. 2009;30(6):643–651. doi:10.1111/j.1365-2036.2009.04074.x.
  • Beh KH, Chuah KH, Mahamad Rappek NA, Mahadeva S, Lin C-Y. The association of body mass index with functional dyspepsia is independent of psychological morbidity: a cross-sectional study. PLOS ONE. 2021;16(1):1–13. doi:10.1371/journal.pone.0245511.
  • Mahadeva S, Goh KL. Anxiety, depression and quality of life differences between functional and organic dyspepsia. J Gastroenterol Hepatol (Australia). 2011;26(s3):49–52. doi:10.1111/j.1440-1746.2011.06656.x.
  • Waters AM, Schilpzand E, Bell C, Walker LS, Baber K. Functional gastrointestinal symptoms in children with anxiety disorders. J Abnorm Child Psychol. 2013;41(1):151–163. doi:10.1007/s10802-012-9657-0.
  • Hosseinzadeh ST, Poorsaadati S, Radkani B, Forootan M. Psychological disorders in patients with chronic constipation. Gastroenterol Hepatol Bed Bench. 2011;4(3):159–163. doi:10.1177/1756283X11401773.
  • Liang J, Zhao Y, Xi Y, Xiang C, Yong C, Huo J, Zou H, Hou Y, Pan Y, Wu M. et al. Association between depression, anxiety symptoms and gut microbiota in Chinese elderly with functional constipation. Nutrients. 2022;14(23):14. doi:10.3390/nu14235013.
  • Sangari RS, Hashemi M, Salehi B, Yousefichaijan P, Rafiei M, Rezagholizamenjany M. Anxiety disorders in children with functional constipation: a case-control study. J Compr Pediatr. 2022;13(2). doi:10.5812/compreped.119997.
  • Bharucha AE, Mechanisms LB. Evaluation, and management of chronic constipation. Gastroenterology. 2020;158(5):1232–1249. doi:10.1053/j.gastro.2019.12.034.
  • Eijsbouts C, Zheng T, Kennedy NA, Bonfiglio F, Anderson CA, Moutsianas L, Holliday J, Shi J, Shringarpure S, Agee M. et al. Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. Nat Genet. 2021;53(11):1543–1552. doi:10.1038/s41588-021-00950-8.
  • Sykes MA, Blanchard EB, Lackner J, Keefer L, Krasner S. Psychopathology in irritable bowel syndrome: support for a psychophysiological model. J Behav Med. 2003;26(4):361–372. doi:10.1023/A:1024209111909.
  • Aro P, Talley NJ, Ronkainen J, Storskrubb T, Vieth M, Johansson SE, Bolling-Sternevald E, Agréus L. Anxiety is associated with uninvestigated and functional dyspepsia (Rome III Criteria) in a Swedish population-based study. Gastroenterology. 2009;137(1):94–100. doi:10.1053/j.gastro.2009.03.039.
  • Koloski NA, Jones M, Kalantar J, Weltman M, Zaguirre J, Talley NJ. The brain–gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut. 2012;61(9):1284–1290. doi:10.1136/gutjnl-2011-300474.
  • Koloski NA, Jones M, Talley NJ. Evidence that independent gut-to-brain and brain-to-gut pathways operate in the irritable bowel syndrome and functional dyspepsia: a 1-year population-based prospective study. Aliment Pharmacol Ther. 2016;44(6):592–600. doi:10.1111/apt.13738.
  • Sjölund J, Kull I, Bergström A, Ljótsson B, Törnblom H, Olén O, Simrén M. Quality of life and bidirectional gut-brain interactions in irritable bowel syndrome from adolescence to adulthood. Clin Gastroenterol Hepatol. 2023;22(4):858–866. doi:10.1016/j.cgh.2023.09.022.
  • Collins SM, Bercik P. The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology. 2009;136(6):2003–2014. doi:10.1053/j.gastro.2009.01.075.
  • Collins SM. A role for the gut microbiota in IBS. Nat Rev Gastroenterol Hepatol. 2014;11(8):497–505. doi:10.1038/nrgastro.2014.40.
  • van Thiel I, de Jonge W, van den Wijngaard R. Fungal feelings in the irritable bowel syndrome: the intestinal mycobiome and abdominal pain. Gut Microbes. 2023;15(1):15. doi:10.1080/19490976.2023.2168992.
  • Das A, O’Herlihy E, Shanahan F, Pw O, Jeffery IB. The fecal mycobiome in patients with irritable bowel syndrome. Sci Rep. 2021;11(1):1–9. doi:10.1038/s41598-020-79478-6.
  • Ansari MH, Ebrahimi M, Fattahi MR, Gardner MG, Safarpour AR, Faghihi MA, Lankarani KB. Viral metagenomic analysis of fecal samples reveals an enteric virome signature in irritable bowel syndrome. BMC Microbiol. 2020;20(1):1–12. doi:10.1186/s12866-020-01817-4.
  • Coughlan S, Das A, O’Herlihy E, Shanahan F, O’Toole PW, Jeffery IB. The gut virome in irritable bowel syndrome differs from that of controls. Gut Microbes. 2021;13(1):1–15. doi:10.1080/19490976.2021.1887719.
  • Mihindukulasuriya KA, Mars RAT, Johnson AJ, Ward T, Priya S, Lekatz HR, Kalari KR, Droit L, Zheng T, Blekhman R. et al. Multi-omics analyses show disease, diet, and transcriptome interactions with the Virome. Gastroenterology. 2021;161(4):1194–1207. doi:10.1053/j.gastro.2021.06.077.
  • Strathdee SA, Hatfull GF, Mutalik VK, Schooley RT. Phage therapy: from biological mechanisms to future directions. Cell. 2023;186(1):17–31. doi:10.1016/j.cell.2022.11.017.
  • Mearin F. Postinfectious functional gastrointestinal disorders. J Clin Gastroenterol. 2011;45:102–105. doi:10.1097/MCG.0b013e31821fbf58.
  • Jalanka J, Salonen A, Fuentes S, de Vos WM. Microbial signatures in post-infectious irritable bowel syndrome – toward patient stratification for improved diagnostics and treatment. Gut Microbes. 2015;6(6):364–369. doi:10.1080/19490976.2015.1096486.
  • Chaudhary NA, Truelove SC. The irritable colon syndrome. A study of the clinical features, predisposing causes, and prognosis in 130 cases. Q J Med. 1962;31:307–322.
  • Barbara G, Vallance BA, Collins SM. Persistent intestinal neuromuscular dysfunction after acute nematode infection in mice. Gastroenterology. 1997;113(4):1224–1232. doi:10.1053/gast.1997.v113.pm9322517.
  • Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. Br Med J. 1997;314(7083):779–779. doi:10.1136/bmj.314.7083.779.
  • Barbara G, Grover M, Bercik P, Corsetti M, Ghoshal UC, Ohman L, Rajilić-Stojanović M. Rome foundation working team report on post-infection irritable bowel syndrome. Gastroenterology. 2019;156(1):46–58. doi:10.1053/j.gastro.2018.07.011.
  • Balemans D, Mondelaers SU, Cibert-Goton V, Stakenborg N, Aguilera-Lizarraga J, Dooley J, Liston A, Bulmer DC, Vanden Berghe P, Boeckxstaens GE. et al. Evidence for long-term sensitization of the bowel in patients with post-infectious-IBS. Sci Rep. 2017;7(1):1–11. doi:10.1038/s41598-017-12618-7.
  • Thabane M, Marshall JK. Post-infectious irritable bowel syndrome. World J Gastroenterol. 2009;15(29):3591–3596. doi:10.3748/wjg.15.3591.
  • Aguilera-Lizarraga J, Florens MV, Viola MF, Jain P, Decraecker L, Appeltans I, Cuende-Estevez M, Fabre N, Van Beek K, Perna E. et al. Local immune response to food antigens drives meal-induced abdominal pain. Nature. 2021;590(7844):151–156. doi:10.1038/s41586-020-03118-2.
  • Wouters MM, Van Wanrooy S, Nguyen A, Dooley J, Aguilera-Lizarraga J, Van Brabant W, Garcia-Perez JE, Van Oudenhove L, Van Ranst M, Verhaegen J. et al. Psychological comorbidity increases the risk for postinfectious IBS partly by enhanced susceptibility to develop infectious gastroenteritis. Gut. 2016;65(8):1279–1288. doi:10.1136/gutjnl-2015-309460.
  • Marshall JK, Thabane M, Garg AX, Clark WF, Moayyedi P, Collins SM. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut. 2010;59(5):605–611. doi:10.1136/gut.2009.202234.
  • Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology. 2003;125(6):1651–1659. doi:10.1053/j.gastro.2003.09.028.
  • Villani AC, Lemire M, Thabane M, Belisle A, Franchimont D, Marshall JK. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology. 2010;138(4):1502–1513. doi:10.1053/j.gastro.2009.12.049.
  • Swan C, Duroudier NP, Campbell E, Zaitoun A, Hastings M, Dukes GE, Cox J, Kelly FM, Wilde J, Lennon MG. et al. Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFα. Gut. 2013;62(7):985–994. doi:10.1136/gutjnl-2011-301213.
  • World Health Organization. Number of COVID-19 cases reported to WHO. https://data.who.int/dashboards/covid19/cases?n=c.
  • Lamers MM, Beumer J, Van Der VJ, Knoops K, Puschhof J, Breugem TI, Ravelli RBG, Van SJ, Mykytyn AZ, Duimel HQ. et al. SARS-CoV-2 productively infects human gut enterocytes. Science (1979). 2020;369(6499):50–54. doi:10.1126/science.abc1669.
  • Marasco G, Cremon C, Barbaro MR, Cacciari G, Falangone F, Kagramanova A, Bordin D, Drug V, Miftode E, Fusaroli P. et al. Post COVID-19 irritable bowel syndrome. Gut. 2023;72(3):484–492. doi:10.1136/gutjnl-2022-328483.
  • Pimentel M, Lembo A. Microbiome and its role in irritable bowel syndrome. Dig Dis Sci [Internet]. 2020;65(3):829–839. doi:10.1007/s10620-020-06109-5.
  • Klem F, Wadhwa A, Prokop LJ, Sundt WJ, Farrugia G, Camilleri M, Singh S, Prevalence GM. Risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: a systematic review and meta-analysis. Gastroenterology. 2017;152(5):1042–1054. doi:10.1053/j.gastro.2016.12.039.
  • Vajravelu RK, Shapiro JM, Ni J, Thanawala SU, Lewis JD, El-Serag HB. Risk for post-colonoscopy irritable bowel syndrome in patients with and without antibiotic exposure: a retrospective cohort study. Clin Gastroenterol Hepatol. 2022;20(6):e1305–22. doi:10.1016/j.cgh.2021.08.049.
  • Maxwell PR, Rink E, Kumar D, Mendall MA. Antibiotics increase functional abdominal symptoms. Am J Gastroenterol. 2002;97(1):104–108. doi:10.1111/j.1572-0241.2002.05428.x.
  • Paula H, Grover M, Halder SL, Locke GR, Schleck CD, Zinsmeister AR, Talley NJ. Non-enteric infections, antibiotic use, and risk of development of functional gastrointestinal disorders. Neurogastroent Motil. 2015;27(11):1580–1586. doi:10.1111/nmo.12655.
  • Baldassarre ME, Di Mauro A, Salvatore S, Tafuri S, Bianchi FP, Dattoli E, Morando L, Pensabene L, Meneghin F, Dilillo D. et al. Birth weight and the development of functional gastrointestinal disorders in infants. Pediatr Gastroenterol Hepatol Nutr. 2020;23(4):366–376. doi:10.5223/pghn.2020.23.4.366.
  • Marasco G, Cremon C, Barbaro MR, Stanghellini V, Barbara G. Gut microbiota signatures and modulation in irritable bowel syndrome. Microbiome Res Rep. 2022;1:1–12. doi:10.20517/mrr.2021.12.
  • Duan R, Zhu S, Wang B, Duan L. Alterations of gut microbiota in patients with irritable bowel syndrome based on 16s rRNA-targeted sequencing: a systematic review. Clin Transl Gastroenterol. 2019;10(2):e00012. doi:10.14309/ctg.0000000000000012.
  • Jeffery IB, Toole PWO, Lena O, Claesson MJ, Deane J, Quigley EMM, Simre M. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut. 2012;61(7):997–1006. doi:10.1136/gutjnl-2011-301501.
  • Jeffery IB, Das A, O’Herlihy E, Coughlan S, Cisek K, Moore M, Bradley F, Carty T, Pradhan M, Dwibedi C. et al. Differences in fecal microbiomes and metabolomes of people with vs without irritable bowel syndrome and bile acid malabsorption. Gastroenterology. 2020;158(4):1016–1028. doi:10.1053/j.gastro.2019.11.301.
  • Jacobs JP, Lagishetty V, Hauer MC, Labus JS, Dong TS, Toma R, Vuyisich M, Naliboff BD, Lackner JM, Gupta A. et al. Multi-omics profiles of the intestinal microbiome in irritable bowel syndrome and its bowel habit subtypes. Microbiome. 2023;11(1):1–18. doi:10.1186/s40168-022-01450-5.
  • Pittayanon R, Lau JT, Yuan Y, Leontiadis GI, Tse F, Surette M, Moayyedi P. Gut microbiota in patients with irritable bowel syndrome—a systematic review. Gastroenterology. 2019;157(1):97–108. doi:10.1053/j.gastro.2019.03.049.
  • Vich Vila A, Imhann F, Collij V, Jankipersadsing SA, Gurry T, Mujagic Z, Kurilshikov A, Bonder MJ, Jiang X, Tigchelaar EF. et al. Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome. Sci Transl Med. 2018;10(472):1–12. doi:10.1126/scitranslmed.aap8914.
  • Tap J, Derrien M, Törnblom H, Brazeilles R, Cools-Portier S, Doré J, Störsrud S, Le Nevé B, Öhman L, Simrén M. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology. 2017;152(1):111–123. doi:10.1053/j.gastro.2016.09.049.
  • Pozuelo M, Panda S, Santiago A, Mendez S, Accarino A, Santos J, Guarner F, Azpiroz F, Manichanh C. Reduction of butyrate- and methane-producing microorganisms in patients with irritable bowel syndrome. Sci Rep. 2015;5(1):1–12. doi:10.1038/srep12693.
  • Liu HN, Wu H, Chen YZ, Chen YJ, Shen XZ, Liu TT. Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: a systematic review and meta-analysis. Dig Liver Dis. 2017;49(4):331–337. doi:10.1016/j.dld.2017.01.142.
  • Labus JS, Hollister EB, Jacobs J, Kirbach K, Oezguen N, Gupta A, Acosta J, Luna RA, Aagaard K, Versalovic J. et al. Differences in gut microbial composition correlate with regional brain volumes in irritable bowel syndrome. Microbiome. 2017;5(1):1–17. doi:10.1186/s40168-017-0260-z.
  • Zhong L, Shanahan ER, Raj A, Koloski NA, Fletcher L, Morrison M, Walker MM, Talley NJ, Holtmann G. Dyspepsia and the microbiome: time to focus on the small intestine. Gut. 2017;66(6):1168–1169. doi:10.1136/gutjnl-2016-312574.
  • Brown G, Hoedt EC, Keely S, Shah A, Walker MM, Holtmann G, Talley NJ. Role of the duodenal microbiota in functional dyspepsia. Neurogastroent Motil. 2022;34(11):1–16. doi:10.1111/nmo.14372.
  • Leite G, Rezaie A, Mathur R, Barlow GM, Rashid M, Hosseini A, Wang J, Parodi G, Villanueva-Millan MJ, Sanchez M. et al. Defining small intestinal bacterial overgrowth by culture and high throughput sequencing. Clin Gastroenterol Hepatol. 2024;22(2):259–270. doi:10.1016/j.cgh.2023.06.001.
  • Shah A, Talley NJ, Jones M, Kendall BJ, Koloski N, Walker MM, Morrison M, Holtmann GJ. Small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis of case-control studies. Am J Gastroenterol. 2020;115(2):190–201. doi:10.14309/ajg.0000000000000504.
  • Gandhi A, Shah A, Jones MP, Koloski N, Talley NJ, Morrison M, Holtmann G. Methane positive small intestinal bacterial overgrowth in inflammatory bowel disease and irritable bowel syndrome: a systematic review and meta-analysis. Gut Microbes. 2021;13(1):1–16. doi:10.1080/19490976.2021.1933313.
  • Ghoshal UC, Nehra A, Mathur A, Rai S. A meta-analysis on small intestinal bacterial overgrowth in patients with different subtypes of irritable bowel syndrome. J Gastroenterol Hepatol (Australia). 2020;35(6):922–931. doi:10.1111/jgh.14938.
  • Mars RAT, Frith M, Kashyap PC. Functional gastrointestinal disorders and the microbiome—what is the best strategy for moving microbiome-based therapies for functional gastrointestinal disorders into the clinic? Gastroenterology. 2021;160(2):538–555. doi:10.1053/j.gastro.2020.10.058.
  • Maharshak N, Ringel Y, Katibian D, Lundqvist A, Sartor RB, Carroll IM, Ringel-Kulka T. Fecal and Mucosa-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Dig Dis Sci. 2018;63(7):1890–1899. doi:10.1007/s10620-018-5086-4.
  • Matsumoto H, Shiotani A, Katsumata R, Fukushima S, Handa Y, Osawa M, Murao T, Handa O, Umegaki E, Inoue R. et al. Mucosa-associated microbiota in patients with irritable bowel syndrome: a comparison of subtypes. Digestion. 2021;102(1):49–56. doi:10.1159/000512167.
  • Rangel I, Sundin J, Fuentes S, Repsilber D, De Vos WM, Brummer RJ. The relationship between faecal-associated and mucosal-associated microbiota in irritable bowel syndrome patients and healthy subjects. Aliment Pharmacol Ther. 2015;42(10):1211–1221. doi:10.1111/apt.13399.
  • Wu BY, Xu P, Cheng L, Wang QQ, Qiu HY, Yan XJ, Chen SL. Mucosa-associated microbiota dysbiosis in the terminal ileum correlates with bowel symptoms in diarrhea-predominant irritable bowel syndrome. Clin Transl Gastroenterol. 2023;13:1–11. Publish Ah.
  • Kerckhoffs APM, Ben-Amor K, Samsom M, Van Der Rest ME, De Vogel J, Knol J, Akkermans LMA. Molecular analysis of faecal and duodenal samples reveals significantly higher prevalence and numbers of Pseudomonas aeruginosa in irritable bowel syndrome. J Med Microbiol. 2011;60(2):236–245. doi:10.1099/jmm.0.022848-0.
  • Bednarska O, Walter SA, Casado-Bedmar M, Ström M, Salvo-Romero E, Vicario M, Mayer EA, Keita ÅV. VIP and mast cells regulate increased passage of colonic bacteria in patients with irritable bowel syndrome. Gastroenterology. 2017;153(4):948–960.e3. doi:10.1053/j.gastro.2017.06.051.
  • Hanning N, Edwinson AL, Ceuleers H, Peters SA, De Man JG, Hassett LC, De Winter BY, Grover M. Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review. Therap Adv Gastroenterol. 2021;14:1–31. doi:10.1177/1756284821993586.
  • Shimbori C, De Palma G, Baerg L, Lu J, Verdu EF, Reed DE, Vanner S, Collins SM, Bercik P. Gut bacteria interact directly with colonic mast cells in a humanized mouse model of IBS. Gut Microbes. 2022;14(1):1–9. doi:10.1080/19490976.2022.2105095.
  • Keshteli AH, Madsen KL, Mandal R, Boeckxstaens GE, Bercik P, De Palma G, Reed DE, Wishart D, Vanner S, Dieleman LA. Comparison of the metabolomic profiles of irritable bowel syndrome patients with ulcerative colitis patients and healthy controls: new insights into pathophysiology and potential biomarkers. Aliment Pharmacol Ther. 2019;49(6):723–732. doi:10.1111/apt.15141.
  • Su Q, Tun HM, Liu Q, Yeoh YK, Mak JWY, Chan FKL, Ng SC. Gut microbiome signatures reflect different subtypes of irritable bowel syndrome. Gut Microbes. 2023;15(1):2157697. doi:10.1080/19490976.2022.2157697.
  • Mujagic Z, Kasapi M, Jonkers DMAE, Garcia-Perez I, Vork L, Weerts ZZRM, Serrano-Contreras JI, Zhernakova A, Kurilshikov A, Scotcher J. et al. Integrated fecal microbiome–metabolome signatures reflect stress and serotonin metabolism in irritable bowel syndrome. Gut Microbes. 2022;14(1):2063016. doi:10.1080/19490976.2022.2063016.
  • Han L, Zhao L, Zhou Y, Yang C, Xiong T, Lu L, Deng Y, Luo W, Chen Y, Qiu Q. et al. Altered metabolome and microbiome features provide clues in understanding irritable bowel syndrome and depression comorbidity. Isme J. 2022;16(4):983–996. doi:10.1038/s41396-021-01123-5.
  • Camilleri M, Vijayvargiya P. The role of bile acids in chronic diarrhea. Am J Gastroenterol. 2020;115(10):1596–1603. doi:10.14309/ajg.0000000000000696.
  • Marasco G, Cremon C, Barbaro MR, Falangone F, Montanari D, Capuani F, Mastel G, Stanghellini V, Barbara G. Pathophysiology and clinical management of bile acid diarrhea. J Clin Med. 2022;11(11):3102. doi:10.3390/jcm11113102.
  • Camilleri M, Carlson P, Bousaba J, McKinzie S, Vijayvargiya P, Magnus Y, Sannaa W, Wang XJ, Chedid V, Zheng T. et al. Comparison of biochemical, microbial and mucosal mRNA expression in bile acid diarrhoea and irritable bowel syndrome with diarrhoea. Gut. 2023;72(1):54–65. doi:10.1136/gutjnl-2022-327471.
  • Gargari G, Taverniti V, Gardana C, Cremon C, Canducci F, Pagano I, Barbaro MR, Bellacosa L, Castellazzi AM, Valsecchi C. et al. Fecal Clostridiales distribution and short-chain fatty acids reflect bowel habits in irritable bowel syndrome. Environ Microbiol. 2018;20(9):3201–3213. doi:10.1111/1462-2920.14271.
  • Bennet SM, Keshteli AH, Bercik P, Madsen KL, Reed D, Vanner SJ. Application of metabolomics to the study of irritable bowel syndrome. Neurogastroent Motil. 2020;32(6):e13884. doi:10.1111/nmo.13884.
  • De Palma G, Lynch MDJ, Lu J, Dang VT, Deng Y, Jury J, Umeh G, Miranda PM, Pastor MP, Sidani S. et al. Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice. Sci Transl Med. 2017;9(379):1–15. doi:10.1126/scitranslmed.aaf6397.
  • De Palma G, Shimbori C, Reed DE, Yu Y, Rabbia V, Lu J, Jimenez-Vargas N, Sessenwein J, Lopez-Lopez C, Pigrau M. et al. Histamine production by the gut microbiota induces visceral hyperalgesia through histamine 4 receptor signaling in mice. Sci Transl Med. 2022;14(655):1–13. doi:10.1126/scitranslmed.abj1895.
  • Tuck CJ, Abu Omar A, De Palma G, Osman S, Jiménez-Vargas NN, Yu Y, Bennet SMP, Lopez-Lopez C, Jaramillo-Polanco JO, Baker CC. et al. Changes in signalling from faecal neuroactive metabolites following dietary modulation of IBS pain. Gut. 2023;72(9):1678–1691. doi:10.1136/gutjnl-2022-327260.
  • Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett NW. et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126(3):693–702. doi:10.1053/j.gastro.2003.11.055.
  • Barbara G, Wang B, Stanghellini V, de Giorgio R, Cremon C, Di Nardo G, Trevisani M, Campi B, Geppetti P, Tonini M. et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology. 2007;132(1):26–37. doi:10.1053/j.gastro.2006.11.039.
  • Balemans D, Aguilera-Lizarraga J, Florens MV, Jain P, Denadai-Souza A, Viola MF, Alpizar YA, Van Der Merwe S, Vanden Berghe P, Talavera K. et al. Histamine-mediated potentiation of transient receptor potential (TRP) ankyrin 1 and TRP vanilloid 4 signaling in submucosal neurons in patients with irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2019;316(3):G338–49. doi:10.1152/ajpgi.00116.2018.
  • Wouters MM, Balemans D, Van Wanrooy S, Dooley J, Cibert-Goton V, Alpizar YA, Valdez-Morales EE, Nasser Y, Van Veldhoven PP, Vanbrabant W. et al. Histamine receptor H1–mediated sensitization of TRPV1 mediates visceral hypersensitivity and symptoms in patients with irritable bowel syndrome. Gastroenterology. 2016;150(4):875–887. doi:10.1053/j.gastro.2015.12.034.
  • Decraecker L, De LD, Hirsch DP, De SH, Arts J, Caenepeel P, Bredenoord AJ, Kolkman J, Bellens K, Van BK. et al. Treatment of non-constipated irritable bowel syndrome with the histamine 1 receptor antagonist ebastine: a randomised, double-blind, placebo-controlled trial. Gut. 2024;73:459–469. doi:10.1136/gutjnl-2023-331634.
  • Khasawneh M, Black CJ, Ford AC. Efficacy of drugs acting on histamine 1 receptors in irritable bowel syndrome: systematic review and meta-analysis. Gastroenterology. 2024 Mar. 16:S0016–5085(24)00297–X. doi:10.1053/j.gastro.2024.03.014.
  • Edwinson AL, Yang L, Peters S, Hanning N, Jeraldo P, Jagtap P, Simpson JB, Yang TY, Kumar P, Mehta S. et al. Gut microbial β-glucuronidases regulate host luminal proteases and are depleted in irritable bowel syndrome. Nat Microbiol. 2022;7(5):680–694. doi:10.1038/s41564-022-01103-1.
  • Caminero A, Guzman M, Libertucci J, Lomax AE. The emerging roles of bacterial proteases in intestinal diseases. Gut Microbes. 2023;15(1):2181922. doi:10.1080/19490976.2023.2181922.
  • Bhattarai Y, Williams BB, Battaglioli EJ, Whitaker WR, Till L, Grover M, Linden DR, Akiba Y, Kandimalla KK, Zachos NC. et al. Gut microbiota-produced tryptamine activates an epithelial G-protein-coupled receptor to increase colonic secretion. Cell Host Microbe. 2018;23(6):775–785. doi:10.1016/j.chom.2018.05.004.
  • Keefer L, Ko CW, Ford AC. AGA clinical practice update on management of chronic gastrointestinal pain in disorders of gut–brain interaction: expert review. Clin Gastroenterol Hepatol. 2021;19(12):2481–2488. doi:10.1016/j.cgh.2021.07.006.
  • Lembo A, Sultan S, Chang L, Heidelbaugh JJ, Smalley W, Verne GN. AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with diarrhea. Gastroenterology. 2022;163(1):137–151. doi:10.1053/j.gastro.2022.04.017.
  • Ford AC, Wright-Hughes A, Alderson SL, Ow PL, Ridd MJ, Foy R, Bianco G, Bishop FL, Chaddock M, Cook H. et al. Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10414):1773–1785. doi:10.1016/S0140-6736(23)01523-4.
  • Borup C, Vinter-Jensen L, Jørgensen SPG, Wildt S, Graff J, Gregersen T, Zaremba A, Borup Andersen T, Nøjgaard C, Timm HB. Efficacy and safety of colesevelam for the treatment of bile acid diarrhoea: a double-blind, randomised, placebo-controlled, phase 4 clinical trial. Lancet Gastroenterol Hepatol. 2023;8(4):321–331. doi:10.1016/S2468-1253(22)00401-0.
  • Li B, Zhang J, Chen Y, Wang Q, Yan L, Wang R, Wei Y, You Z, Li Y, Miao Q. et al. Alterations in microbiota and their metabolites are associated with beneficial effects of bile acid sequestrant on icteric primary biliary Cholangitis. Gut Microbes. 2021;13(1):1946366. doi:10.1080/19490976.2021.1946366.
  • Kumar A, Quraishi MN, Al-Hassi HO, El-Asrag ME, Segal JP, Jain M, Steed H, Butterworth J, Farmer A, Mclaughlin J. et al. The analysis of gut microbiota in patients with bile acid diarrhoea treated with colesevelam. Front Microbiol. 2023;14:1–11. doi:10.3389/fmicb.2023.1134105.
  • Black CJ, Ford AC. How effective are antibiotics for the treatment of irritable bowel syndrome? Expert Opin Pharmacother. 2020;21(18):2195–2197. doi:10.1080/14656566.2020.1808623.
  • Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98(2):412–419. doi:10.1111/j.1572-0241.2003.07234.x.
  • Ghoshal UC, Srivastava D, Misra A, Ghoshal U. A proof-of-concept study showing antibiotics to be more effective in irritable bowel syndrome with than without small-intestinal bacterial overgrowth: a randomized, double-blind, placebo-controlled trial. Eur J Gastroenterol Hepatol. 2016;28(3):281–289. doi:10.1097/MEG.0000000000000557.
  • Acosta A, Camilleri M, Shin A, Nord SL, Neill JO, Gray AV, Lueke AJ, Donato LJ, Burton DD, Szarka LA. et al. Effects of rifaximin on transit, permeability, fecal microbiome, and organic acid excretion in irritable bowel syndrome. Clin Transl Gastroenterol. 2016;7(5):e173. doi:10.1038/ctg.2016.32.
  • Black CJ, Burr NE, Camilleri M, Earnest DL, Quigley EMM, Moayyedi P, Houghton LA, Ford AC. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. Gut 2020;69(1):74–82. doi:10.1136/gutjnl-2018-318160.
  • Ponziani FR, Scaldaferri F, De Siena M, Mangiola F, Matteo MV, Pecere S, Petito V, Paroni Sterbini F, Lopetuso LR, Masucci L. et al. Increased Faecalibacterium abundance is associated with clinical improvement in patients receiving rifaximin treatment. Benef Microbes. 2020;11(6):519–525. doi:10.3920/BM2019.0171.
  • Pimentel M. Review article: Potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther. 2016;43(S1):37–49. doi:10.1111/apt.13437.
  • Champagne-Jorgensen K, Kunze WA, Forsythe P, Bienenstock J, McVey Neufeld KA. Antibiotics and the nervous system: more than just the microbes? Brain Behav Immun. 2019;77:7–15. doi:10.1016/j.bbi.2018.12.014.
  • Xu D, Gao J, Gillilland M, Wu X, Song I, Kao JY, Owyang C. Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterology. 2014;146(2):484–496.e4. doi:10.1053/j.gastro.2013.10.026.
  • Macedo D, Filho AJMC, de Sousa C, Quevedo J, Barichello T, Júnior HVN, Freitas de Lucena D. Antidepressants, antimicrobials or both? Gut microbiota dysbiosis in depression and possible implications of the antimicrobial effects of antidepressant drugs for antidepressant effectiveness. Journal Of Affective Disorders. 2017;208:22–32. doi:10.1016/j.jad.2016.09.012.
  • Fung TC, Vuong HE, Luna CDG, Pronovost GN, Aleksandrova AA, Riley NG, Vavilina A, McGinn J, Rendon T, Forrest LR. et al. Intestinal serotonin and fluoxetine exposure modulate bacterial colonization in the gut. Nat Microbiol. 2019;4(12):2064–2073. doi:10.1038/s41564-019-0540-4.
  • Varma R, Staab JP, Matey ET, Wright JA, Deb B, Lazaridis KN, Szarka LA, Bailey KR, Bharucha AE. Most patients with disorders of gut-brain interaction receive pharmacotherapy with major or moderate drug-gene interactions. Neurogastroent Motil. 2023;36(2):1–13. doi:10.1111/nmo.14722.
  • Chey WD, Hashash JG, Manning L, Chang L. AGA clinical practice update on the role of diet in irritable bowel syndrome: expert review. Gastroenterology. 2022;162(6):1737–1745.e5. doi:10.1053/j.gastro.2021.12.248.
  • De Palma G, Reed DE, Bercik P. Diet–microbial cross–talk underlying increased visceral perception. Gut Microbes. 2023;15(1):2166780. doi:10.1080/19490976.2023.2166780.
  • De Palma G, Bercik P. Long-term personalized low FODMAP diet in IBS. Neurogastroent Motil. 2022;34(4):1–6. doi:10.1111/nmo.14356.
  • Algera JP, Magnusson MK, Öhman L, Störsrud S, Simrén M, Törnblom H. Randomised controlled trial: effects of gluten-free diet on symptoms and the gut microenvironment in irritable bowel syndrome. Aliment Pharmacol Ther. 2022;56(9):1318–1327. doi:10.1111/apt.17239.
  • Pinto-Sanchez MI, Nardelli A, Borojevic R, De Palma G, Calo NC, McCarville J, Caminero A, Basra D, Mordhorst A, Ignatova E. et al. Gluten-free diet reduces symptoms, particularly diarrhea, in patients with irritable bowel syndrome and antigliadin IgG. Clin Gastroenterol Hepatol. 2021;19(11):2343–2352. doi:10.1016/j.cgh.2020.08.040.
  • Savarino E, Zingone F, Barberio B, Marasco G, Akyuz F, Akpinar H, Barboi O, Bodini G, Bor S, Chiarioni G. et al. Functional bowel disorders with diarrhoea: clinical guidelines of the United European gastroenterology and European society for neurogastroenterology and motility. United European Gastroenterol J. 2022;10(6):556–584. doi:10.1002/ueg2.12259.
  • Dionne J, Ford AC, Yuan Y, Chey WD, Lacy BE, Saito YA, Quigley EMM, Moayyedi P. A systematic review and meta-analysis evaluating the efficacy of a gluten-free diet and a low FODMAPs diet in treating symptoms of irritable bowel syndrome. Am J Gastroenterol. 2018;113(9):1290–1300. doi:10.1038/s41395-018-0195-4.
  • Mohseni F, Agah S, Ebrahimi-Daryani N, Taher M, Nattagh-Eshtivani E, Karimi S, Rastgoo S, Bourbour F, Hekmatdoost A. The effect of low FODMAP diet with and without gluten on irritable bowel syndrome: a double blind, placebo controlled randomized clinical trial. Clin Nutr ESPEN. 2022;47:45–50. doi:10.1016/j.clnesp.2021.12.019.
  • Bojarski C, Tangermann P, Barmeyer C, Buchkremer J, Kiesslich R, Ellrichmann M, Schreiber S, Schmidt C, Stallmach A, Roehle R. et al. Prospective, double-blind diagnostic multicentre study of confocal laser endomicroscopy for wheat sensitivity in patients with irritable bowel syndrome. Gut. 2022;71(8):1567–1576. doi:10.1136/gutjnl-2021-325181.
  • Gibson PR, Halmos EP, So D, Yao CK, Varney JE, Muir JG. Diet as a therapeutic tool in chronic gastrointestinal disorders: Lessons from the FODMAP journey. J Gastroenterol Hepatol (Australia). 2022;37(4):644–652. doi:10.1111/jgh.15772.
  • Caminero A, McCarville JL, Zevallos VF, Pigrau M, Yu XB, Jury J, Galipeau HJ, Clarizio AV, Casqueiro J, Murray JA. et al. Lactobacilli degrade wheat amylase trypsin inhibitors to reduce intestinal dysfunction induced by immunogenic wheat proteins. Gastroenterology. 2019;156(8):2266–2280. doi:10.1053/j.gastro.2019.02.028.
  • Caminero A, Galipeau HJ, McCarville JL, Johnston CW, Bernier SP, Russell AK, Jury J, Herran AR, Casqueiro J, Tye-Din JA. et al. Duodenal bacteria from patients with celiac disease and healthy subjects distinctly affect gluten breakdown and immunogenicity. Gastroenterology. 2016;151(4):670–683. doi:10.1053/j.gastro.2016.06.041.
  • Seiler C, Rueda G, Miranda P, Nardelli A, Borojevic R, Schuppan D, Moayyedi P, Verdu EF, Collins SM, Pinto-Sanchez MI. et al. 683 investigating mechanisms that drive symptoms in patients with irritable bowel syndrome and perceived gluten sensitivity. Gastroenterology. 2023;164(6):S-136–S–137. doi:10.1016/S0016-5085(23)01290-8.
  • Wu J, Masuy I, Biesiekierski JR, Fitzke HE, Parikh C, Schofield L, Shaikh H, Bhagwanani A, Aziz Q, Taylor SA. et al. Gut-brain axis dysfunction underlies FODMAP-induced symptom generation in irritable bowel syndrome. Aliment Pharmacol Ther. 2022;55(6):670–682. doi:10.1111/apt.16812.
  • Black CJ, Staudacher HM, Ford AC. Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. Gut. 2022;71(6):1117–1126. doi:10.1136/gutjnl-2021-325214.
  • Gunn D, Abbas Z, Harris HC, Major G, Hoad C, Gowland P, Marciani L, Gill SK, Warren FJ, Rossi M. et al. Psyllium reduces inulin-induced colonic gas production in IBS: MRI and in vitro fermentation studies. Gut. 2022;71(5):919–927. doi:10.1136/gutjnl-2021-324784.
  • McIntosh K, Reed DE, Schneider T, Dang F, Keshteli AH, De Palma G, Madsen K, Bercik P, Vanner S. FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial. Gut. 2017;66(7):1241–1251. doi:10.1136/gutjnl-2015-311339.
  • Zhou SY, Gillilland M, Wu X, Leelasinjaroen P, Zhang G, Zhou H, Ye B, Lu Y, Owyang C. FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction. J Clin Invest. 2018;128(1):267–280. doi:10.1172/JCI92390.
  • Singh P, Grabauskas G, Zhou SY, Gao J, Zhang Y, Owyang C. High FODMAP diet causes barrier loss via lipopolysaccharide-mediated mast cell activation. JCI Insight. 2021;6(22):6. doi:10.1172/jci.insight.146529.
  • Yang R, Jiang J, Ouyang J, Zhao Y, Xi B. Efficacy and safety of probiotics in irritable bowel syndrome: a systematic review and meta-analysis. Clin Nutr ESPEN. 2024;60:362–372. doi:10.1016/j.clnesp.2024.02.025.
  • Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, Moshiree B. ACG Clinical Guideline: management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021;116(1):17–44. doi:10.14309/ajg.0000000000001036.
  • Moshiree B, Drossman D, Shaukat A. AGA clinical practice update on evaluation and management of belching, abdominal bloating, and distention: expert review. Gastroenterology [Internet]. 2023;165(3):791–800. doi:10.1053/j.gastro.2023.04.039.
  • Goodoory VC, Khasawneh M, Black CJ, Quigley EMM, Moayyedi P, Ford AC. Efficacy of probiotics in irritable bowel syndrome: systematic review and meta-analysis. Gastroenterology [Internet]. 2023;165(5):1206–1218. doi:10.1053/j.gastro.2023.07.018.
  • Di Nardo G, Barbara G, Borrelli O, Cremon C, Giorgio V, Greco L, La Pietra M, Marasco G, Pensabene L, Piccirillo M. et al. Italian guidelines for the management of irritable bowel syndrome in children and adolescents. Ital J Pediatr. 2024;50(1):1–23. doi:10.1186/s13052-024-01607-y.
  • Pinto-Sanchez MI, Hall GB, Ghajar K, Nardelli A, Bolino C, Lau JT, Martin FP, Cominetti O, Welsh C, Rieder A. et al. Probiotic Bifidobacterium longum NCC3001 reduces depression scores and alters brain activity: a pilot study in patients with irritable bowel syndrome. Gastroenterology. 2017;153(2):448–459. doi:10.1053/j.gastro.2017.05.003.
  • Meynier M, Daugey V, Mallaret G, Gervason S, Meleine M, Barbier J, Aissouni Y, Lolignier S, Bonnet M, Ardid D. et al. Pasteurized akkermansia muciniphila improves irritable bowel syndrome-like symptoms and related behavioral disorders in mice. Gut Microbes. 2024;16(1):2298026. doi:10.1080/19490976.2023.2298026.
  • Constante M, De Palma G, Lu J, Jury J, Rondeau L, Caminero A, Collins SM, Verdu EF, Bercik P. Saccharomyces boulardii CNCM I-745 modulates the microbiota–gut–brain axis in a humanized mouse model of irritable bowel syndrome. Neurogastroent Motil. 2021;33(3):1–9. doi:10.1111/nmo.13985.
  • van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JFWM, Tijssen JGP. et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407–415. doi:10.1056/NEJMoa1205037.
  • Holvoet T, Joossens M, Vázquez-Castellanos JF, Christiaens E, Heyerick L, Boelens J, Verhasselt B, van Vlierberghe H, De Vos M, Raes J. et al. Fecal microbiota transplantation reduces symptoms in some patients with irritable bowel syndrome with predominant abdominal bloating: short- and long-term results from a placebo-controlled randomized trial. Gastroenterology. 2021;160(1):145–157. doi:10.1053/j.gastro.2020.07.013.
  • El-Salhy M, Winkel R, Casen C, Hausken T, Gilja OH, Hatlebakk JG. Efficacy of fecal microbiota transplantation for patients with irritable bowel syndrome at 3 years after transplantation. Gastroenterology. 2022;163(4):982–994. doi:10.1053/j.gastro.2022.06.020.
  • Rokkas T, Hold GL. A systematic review, pairwise meta-analysis and network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2023;35(4):471–479. doi:10.1097/MEG.0000000000002519.
  • Halkjær SI, Lo B, Cold F, Christensen AH, Holster S, König J, Brummer RJ, Aroniadis OC, Lahtinen P, Holvoet T. et al. Fecal microbiota transplantation for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. World J Gastroenterol. 2023;29(20):3185–3202. doi:10.3748/wjg.v29.i20.3185.
  • El-Salhy M, Gilja OH, Hatlebakk JG. Factors affecting the outcome of fecal microbiota transplantation for patients with irritable bowel syndrome. Neurogastroent Motil. 2024;36(1):e14641. doi:10.1111/nmo.14641.
  • Ianiro G, Punčochář M, Karcher N, Porcari S, Armanini F, Asnicar F, Beghini F, Blanco-Míguez A, Cumbo F, Manghi P. et al. Variability of strain engraftment and predictability of microbiome composition after fecal microbiota transplantation across different diseases. Nat Med. 2022;28(9):1913–1923. doi:10.1038/s41591-022-01964-3.
  • Black CJ, Thakur ER, Houghton LA, Quigley EMM, Moayyedi P, Ford AC. Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. Gut. 2020;69(8):1441–1451. doi:10.1136/gutjnl-2020-321191.
  • Lackner JM, Jaccard J, Keefer L, Brenner DM, Firth RS, Gudleski GD, Hamilton FA, Katz LA, Krasner SS, Ma CX. et al. Improvement in gastrointestinal symptoms after cognitive behavior therapy for refractory irritable bowel syndrome. Gastroenterology. 2018;155(1):47–57. doi:10.1053/j.gastro.2018.03.063.
  • Jacobs JP, Gupta A, Bhatt RR, Brawer J, Gao K, Tillisch K, Lagishetty V, Firth R, Gudleski GD, Elligson BM. et al. Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome. 2021;9(1):1–14. doi:10.1186/s40168-021-01188-6.
  • Islam Z, D’Silva A, Raman M, Nasser Y. The role of mind body interventions in the treatment of irritable bowel syndrome and fibromyalgia. Front Psychiatry. 2022;13:1076763. doi:10.3389/fpsyt.2022.1076763.
  • D’Silva A, Marshall DA, Vallance JK, Nasser Y, Rajagopalan V, Szostakiwskyj JH, Raman M. Meditation and yoga for irritable bowel syndrome: a randomized clinical trial. Am J Gastroenterol. 2023;118(2):329–337. doi:10.14309/ajg.0000000000002052.
  • Kuttner L, Chambers CT, Hardial J, Israel DM, Jacobson K, Evans K. A randomized trial of yoga for adolescents with irritable bowel syndrome. Pain Res Manag. 2006;11(4):217–224. doi:10.1155/2006/731628.
  • Ljótsson B, Andersson G, Andersson E, Hedman E, Lindfors P, Andréewitch S, Rück C, Lindefors N. Acceptability, effectiveness, and cost-effectiveness of internet-based exposure treatment for irritable bowel syndrome in a clinical sample: a randomized controlled trial. BMC Gastroenterol. 2011;11(1):1–13. doi:10.1186/1471-230X-11-110.
  • Zernicke KA, Campbell TS, Blustein PK, Fung TS, Johnson JA, Bacon SL, Carlson LE. Mindfulness-based stress reduction for the treatment of irritable bowel syndrome symptoms: a randomized wait-list controlled trial. Int J Behav Med. 2013;20(3):385–396. doi:10.1007/s12529-012-9241-6.
  • Evans S, Seidman LC, Lung K, Sternlieb B, Zeltzer LK. Yoga for teens with irritable bowel syndrome: results from a mixed-methods pilot study. Holist Nurs Pract. 2018;32(5):253–260. doi:10.1097/HNP.0000000000000288.
  • Schumann D, Langhorst J, Dobos G, Cramer H. Randomised clinical trial: yoga vs a low-FODMAP diet in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2018;47(2):203–211. doi:10.1111/apt.14400.
  • Taneja I, Deepak KK, Poojary G, Acharya IN, Pandey RM, Sharma MP. Yogic versus conventional treatment in diarrhea-predominant irritable bowel syndrome: a randomized control study. Appl Psychophysiol Biofeedback. 2004;29(1):19–33. doi:10.1023/B:APBI.0000017861.60439.95.
  • Kavuri V, Selvan P, Malamud A, Raghuram N, Selvan SR. Remedial yoga module remarkably improves symptoms in irritable bowel syndrome patients: a 12-week randomized controlled trial. Eur J Integr Med. 2015;7(6):595–608. doi:10.1016/j.eujim.2015.11.001.
  • Shahabi L, Naliboff BD, Shapiro D. Self-regulation evaluation of therapeutic yoga and walking for patients with irritable bowel syndrome: a pilot study. Psychol Health Med. 2016;21(2):176–188. doi:10.1080/13548506.2015.1051557.
  • Lacy BE, Cangemi DJ, Spiegel BR. Virtual reality: a new treatment paradigm for disorders of gut-brain interaction? Gastroenterol Hepatol (N Y). 2023;19(2):86–94.
  • Cangemi DJ, Montenegro M, Spiegel BR, Lacy BE. Virtual reality improves symptoms of functional dyspepsia: results of a randomized, double-blind, sham-controlled, pilot study. Am J Gastroenterol. 2023;119(1):210–213. doi:10.14309/ajg.0000000000002492.
  • Spiegel BMR, Liran O, Gale R, Khalil C, Makaroff K, Chernoff R, Raber T, Chang B, Pichetshote N, Rezaie A. Qualitative validation of a novel VR program for irritable bowel syndrome: a VR1 study. Am J Gastroenterol. 2022;117(3):495–500. doi:10.14309/ajg.0000000000001641.
  • Bonaz B, Bazin T, Pellissier S. The vagus nerve at the interface of the microbiota-gut-brain axis. Front Neurosci. 2018;12:1–9. doi:10.3389/fnins.2018.00049.
  • Shi X, Hu Y, Zhang B, Li W, Chen JDZ, Liu F. Ameliorating effects and mechanisms of transcutaneous auricular vagal nerve stimulation on abdominal pain and constipation. JCI Insight. 2021;6(14):0–18. doi:10.1172/jci.insight.150052.
  • Alam J, Chen JDZ. Non invasive neuromodulation: an emerging intervention for visceral pain in gastrointestinal disorders. Bioelectron Med. 2023;9(1):27. doi:10.1186/s42234-023-00130-5.
  • Yan Q, Chen J, Ren X, Song Y, Xu J, Xuan S, Jiang X, Kuang Z, Tang Z. Vagus nerve stimulation relieves irritable bowel syndrome and the associated depression via α7nAChR-mediated anti-inflammatory pathway. Neuroscience. 2023;530:26–37. doi:10.1016/j.neuroscience.2023.08.026.
  • Krasaelap A, Sood MR, Li BUK, Unteutsch R, Yan K, Nugent M, Simpson P, Kovacic K. Efficacy of auricular neurostimulation in adolescents with irritable bowel syndrome in a randomized, double-blind trial. Clinical Gastroenterology and Hepatology. 2020;18(9):1987–1994. doi:10.1016/j.cgh.2019.10.012.
  • Bora G, Atkinson SN, Pan A, Sood M, Salzman N, Karrento K. Impact of auricular percutaneous electrical nerve field stimulation on gut microbiome in adolescents with irritable bowel syndrome: a pilot study. J Dig Dis. 2023;24(5):348–358. doi:10.1111/1751-2980.13203.
  • Kovacic K, Hainsworth K, Sood M, Chelimsky G, Unteutsch R, Nugent M, Simpson P, Miranda A. Neurostimulation for abdominal pain-related functional gastrointestinal disorders in adolescents: a randomised, double-blind, sham-controlled trial. Lancet Gastroenterol Hepatol. 2017;2(10):727–737. doi:10.1016/S2468-1253(17)30253-4.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.